CARVYKTI significantly extends OS vs standard therapies for patients with multiple myeloma as early as second line October 2, 2024
DARZALEX FASPRO-based quadruplet regimen significantly improves MRD negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned October 1, 2024
Significant New Data from Ph 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer Announced October 1, 2024
Initial Ph 2 Data of BDTX-1535 in Patients with Recurrent EGFRm NSCLC with Classical, Non-classical, and C797S Resistance Mutations Announced October 1, 2024
Positive Initial Safety, Tolerability, PK, and Preliminary Efficacy Data announced from Ph 1 Trial of PAS-004 in Advanced Cancer October 1, 2024
TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) combo yields high response rates and durable responses in triple-class refractory RRMM patients October 1, 2024
FAILED TRIAL: Ph 3 KEYFORM-007 trial of favezelimab + KEYTRUDA did not meet its primary endpoint of OS in patients with previously treated PD-L1+ve MSS mCRC October 1, 2024
Patritumab Deruxtecan Demonstrated Statistically Significant PFS Improvement vs Chemo in Locally Advanced or Metastatic EGFRm NSCLC in HERTHENA-Lung02 Ph 3 Trial September 24, 2024
FAILED TRIAL: Datopotamab deruxtecan did not achieve statistical significance for OS vs chemo in patients with metastatic HR+, HER2-low or neg breast cancer in TROPION-Breast01 Ph 3 trial September 24, 2024
Ph 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study Announced September 24, 2024
Favorable Results Reported for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study September 24, 2024
Positive Preliminary Data Reported in Ph 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer September 24, 2024
Neoadjuvant TAR-200 + cetrelimab nearly doubles the pCRR compared to cetrelimab alone in patients with MIBC September 24, 2024
Zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients September 18, 2024
Datopotamab deruxtecan showed mOS of 14.6 months in patients with advanced nonsquamous NSCLC in TROPION-Lung01 Ph 3 trial September 18, 2024
Additional Positive Efficacy Data with BI-1808 monotherapy from Ph 2a anti-TNFR2 program Announced September 17, 2024
Elraglusib Demonstrated Anti-Tumor Activity with Two Ongoing Durable CRs and ~62% DCR in First 8 Patients with R/R Ewing and Ewing-related Sarcomas September 17, 2024
Encouraging results from expansion part of Ph 1/2 SOHO-01 study of BAY 2927088 in advanced HER2-mutant NSCLC announced September 17, 2024
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced NSCLC September 17, 2024
Median OS of 15.6 months in Ph 2 Bria-IMT™ study patients treated in combination with CPI announced September 17, 2024
FAILED TRIAL: CONTACT-02 Ph 3 mCRC trial did not meet statistical significance of OS endpoint September 17, 2024
